These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1096 related items for PubMed ID: 20132658

  • 1. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W, Zhao J, Wang C, Wang T, Xing Y.
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [Abstract] [Full Text] [Related]

  • 2. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD.
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W, Zhao J, Xing Y, Wang C, Wang T.
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J, Qiao W, Wang C, Wang T, Xing Y.
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [Abstract] [Full Text] [Related]

  • 5. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL.
    Cancer; 2008 Nov 01; 113(9):2496-503. PubMed ID: 18833583
    [Abstract] [Full Text] [Related]

  • 6. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Pötzi C, Raderer M, Dudczak R, Kletter K.
    Leukemia; 2002 Feb 01; 16(2):260-7. PubMed ID: 11840293
    [Abstract] [Full Text] [Related]

  • 7. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):e647-54. PubMed ID: 22607911
    [Abstract] [Full Text] [Related]

  • 8. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.
    Ann Hematol; 2014 Aug 01; 93(8):1297-304. PubMed ID: 24595734
    [Abstract] [Full Text] [Related]

  • 9. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
    You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G.
    Cancer Chemother Pharmacol; 2015 Nov 01; 76(5):939-48. PubMed ID: 26391155
    [Abstract] [Full Text] [Related]

  • 10. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 01; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 11. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Ann Oncol; 2002 Sep 01; 13(9):1356-63. PubMed ID: 12196360
    [Abstract] [Full Text] [Related]

  • 12. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N, Higuchi T, Endo K, Tsukamoto N, Matsuda H, Kuji I, Murakami K, Nakajima K.
    Kaku Igaku; 2009 Jun 01; 46(2):96-9. PubMed ID: 19637820
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ.
    J Nucl Med; 2002 Aug 01; 43(8):1018-27. PubMed ID: 12163626
    [Abstract] [Full Text] [Related]

  • 17. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Haematologica; 2000 Jun 01; 85(6):613-8. PubMed ID: 10870118
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb 01; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 19. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A.
    Cancer; 2012 Oct 01; 118(19):4706-14. PubMed ID: 22252613
    [Abstract] [Full Text] [Related]

  • 20. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.